ASCO 2023 | NORSE: erdafitinib and cetrelimab in urothelial carcinoma

Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the randomized, non-comparative cohort NORSE trial (NCT03473743), which compared two groups of patients who had cisplatin ineligible metastatic urothelial carcinoma. Patients were randomized to receive erdafitinib alone or in combination with cetrelimab. objective response rate (ORR) and complete response (CR) were superior in patients who received combination therapy. Patients treated with erdafitinib monotherapy also had a shorter median progression-free survival and overall survival (OS) compared to the combination cohort. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.